A radiation-free, non-myeloablative, myelosuppressive protocol, containing dibromomannitol and cytosine arabinoside, that remarkably reduced the frequency of transplant-related complications, such as veno-occlusive liver disease (VOLD), severe mucositis, bacterial sepsis, hemorrhagic cystitis, interstitial pneumonitis, has been applied in 19 CML patients, allotransplanted from identical siblings. Five patients were in accelerated phase. Acute GVHD developed in two patients and chronic GVHD occurred in 66% of patients. Follow-up was 3 to 7. years. Although only eight patients were under 30 years of age, and only two patients had a history of less than 1 year, the leukemia-free survival was 82%. There were four hematological relapses. The reduction in post-BMT complications has greatly enhanced quality of life. The nurses reported significant reduction of work-load. Savings in eliminating the need for irradiation, parenteral nutrition, and several antibiotics are also remarkable. The remarkable reduction of certain transplant-related complications shows some advantage against busulphan-preconditioning. Keywords: chronic myeloid leukemia; identical; allogeneic BMT; dibromomannitol-containing non-myeloablative preconditioning; transplant-related complications
We previously proposed that the use of a radiation-free preconditioning protocol containing mitobronitol (dibromomannitol, DBM) as a myelosuppressive agent could improve the therapeutic efficacy of bone marrow transplantation (BMT) in chronic myeloid leukemia (CML) by reducing the frequency and severity of several post-BMT complications. 1 Although the effect was unambiguous, the relatively small number of patients in the study (eight) afforded only a rough estimate of the benefit in quantitative terms. In the present communication, we would like to report our observations on 19 additional CML patients who underwent BMT with DBM preconditioning, and whose results appear to strengthen our claim that this On the basis of our favorable experience with the nonmyeloablative DBM-protocol which is myelosuppressive rather than supralethal, we considered that the eradication of the leukaemic clone may not be mandatory for clinical cure.
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Patients and methods
The observation period was from July 1990 until December 1997, and includes all HLA-identical sibling transplants from July 1990 to December 1994, preconditioned with the DBM-containing protocol, described below. The follow-up period ranged between 3 years, set as a minimum, and 7. years. Five patients were in accelerated phase of the disease with poor outlook, and seven patients were younger than 30 years at the time of BMT. Only two patients had a history of less than 1 year. Against these odds, 17 of 19 patients (89.47%) are alive and 14/17 (82.35%) are free of leukaemia at the time of this report. Successful trilineage engraftment was documented in 17/19 cases.
The conditioning protocol consisted of DBM p.o., 120 mg/kg (all doses in total) on days −9, −8, −7; cytosine arabinoside i.v., 60 mg/kg on days −7, −6 and −5; and cyclophosphamide i.v., 150 mg/kg on days −4, −3 and −2. All doses were evenly distributed over the 3 days. The number of bone marrow cells infused ranged from 1.6 to 5.6 × 10 8 /kg, average: 3 × 10 8 /kg. Short-term methotrexate and cyclosporine were used for prevention of graft-versushost disease (GVHD). We investigated chimerism, in the sixth month, in 16 patients: full chimerism was present in 12, mixed chimerism in three, and no chimerism in one patient. Table 1 shows the incidence of various post-BMT complications. Reduction in the frequency of most complications, with an apparent absence of severe mucositis, veno-occlusive liver disease (VOLD) and bacterial sepsis, indicates highly significant improvement of the therapeutic efficacy of BMT. These changes, on the other hand, were not associated with a reduction of chronic GVHD, which is considered beneficial for the patient because of a simultaneous Table 1 Transplant-related complications of HLA-identical sibling transplants in CML patients observed for more than 3 years and using a relatively mild dibromomannitol-containing conditioning protocol antileukemic effect. Another observation is the post-BMT return of fertility in four of 12 eligible cases. DBM-plasma levels in 18 patients were investigated by Erdélyi-Tóth et al (manuscript in preparation). We did not find low DBM-plasma levels among relapsed patients.
Results
For comparison, the reported long-term survival and frequency of complications following HLA-identical BMT in CML patients at the Seattle BMT center, using busulphancontaining chemotherapy for conditioning (45 patients: 36 in chronic and nine in accelerated phase) are as follows: leukemic relapse 15.5% (12.8% in CP), Ͼgrade II acute GVHD 57% among patients with busulphan plasma levels above the median, extensive chronic GVHD 74%, mucositis 95%, VOLD 34%. No relapse occurred among patients who achieved busulphan levels above the median. The 3-year survival estimate was 82% for patients above the median busulphan levels. 2 Comparing busulphan with total body irradiation as conditioning in 167 allogeneic marrow transplant recipients, Ringden et al 3 found that patients treated with busulphan had an increased incidence of VOD of the liver (12%) and 24% had hemorrhagic cystitis, 26% grade II-IV acute GVHD, and 14% interstitial pneumonitis. There was a 22% relapse rate at 3 years, and the relapsefree survival at 3 years for CML was 67% (30 patients).
The median observation time for our cases is 4 years. If we consider the 4-year results of the International Bone Marrow Center (Milwaukee, USA, 1996) we observe a 57% leukemia-free survival in chronic (2753 patients), and 36% in accelerated (490 patients) CML, while 65% of patients in chronic, and 42% in accelerated phase are alive. Probability of relapse after HLA-identical sibling BMT for CML was 19% among chronic, and 40% among accelerated cases. 4 
Discussion
The latest comprehensive report from the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation based on 373 transplants carried out between 1980 and 1988, for first chronic phase of CML, using unmanipulated marrow cells from HLA-identical sibling donors, merits special attention and can serve as a comparison with other results. 5 Patients conditioned with a non-TBI conditioning regimen, as well as T celldepleted transplants, and patients receiving methotrexate only as GVHD prophylaxis were excluded from the analysis. The median follow-up was 7 years. Acute GVHD developed in 47% of patients. Absence of chronic GVHD was a risk factor for both early and late relapses, whilst male donor sex only increased the risk of late relapse. The probability of relapse occurring more than 2 years after transplant ('late relapse') was increased more than five-fold in patients transplanted from a male donor. Patients with no chronic GVHD and a male donor had an overall probability of relapse of 34.9% compared to only 5.1% for those without chronic GVHD and a female donor. Recipient sex and acute GVHD proved to be significant determinants of leukemia-free survival (LFS). Female recipients who did not develop acute GVHD (II-IV) post-marrow transplant, achieved a LFS of nearly 70%. Conversely, a LFS of only 38% was observed in male recipients of male donor marrow. While 42% of patients transplanted in advanced phase developed severe acute GVHD, 6 only one patient developed a severe form of this syndrome among our eight accelerated (advanced) cases (applying the IBMTR criteria).
Although the number of observations is small, our 6 months survival (17/19) merits mentioning. According to the 1997 edition of a well-known textbook of oncology, in allogeneic bone marrow transplantation for chronic myelogenous leukemia 'in all, 20% to 30% of patients have died from treatment-related complications within 6 months of the procedure'. 7 Apart from the patients described here, we have information on 18 additional cases with a follow-up period of less than 2. years. Except for acute GVHD, the pooled data show no substantial changes in the occurrence of complications: acute GVHD 8/36; VOLD 0/36; severe mucositis 0/36; bacterial sepsis 2/36; invasive fungal infection 2/36; interstitial pneumonitis 2/36; CMV reactivation 3/36; other viral infections 0/36; chronic GVHD 24/36 (19 limited, five extended). The actuarial leukemia-free survival is 75%. 8 Our mild preconditioning, which may also permit considerable lymphoid restoration 9 could explain the relatively rare occurrence of infectious complications. Although the number of our 'eligible' observations is very small, if the pre-1990 patients are included, we have six cases surviving more than 5 years. Quite recently, Apperley et al 10 collected nearly 4000 transplants and formed a score that has prognostic value. Accordingly a patient with a score of 2 (1506 patients) has a 36% probability of leukemia-free survival at 5 years. Six CML patients over 5 years post-transplant with a score of 2 are leukemia-free 61 to 89 months (average 75.5) after BMT. We could consider that DBMconditioning may represent a special subgroup.
Last, but not least, the higher frequency of relapses among our patients is disturbing. Altogether, there were six relapses between 7 and 29 weeks post-transplant, and hematological relapse occurred in four cases. Hitherto no late hematological relapse (2 years or more post-transplant) emerged. Interestingly, there was no relapse among the four patients transplanted in accelerated phase. Although elimination of cytogenetic and/or molecular relapse was achieved in only two of our five cases, administration of donor buffy coat offers significant help to relapsed CML patients. 11 The reductions in post-BMT complications has greatly enhanced quality of life in our patients. The nurses report significant reduction of work load, and savings in eliminating the need for irradiation, parenteral nutrition and antibiotics are also remarkable.
